CN118236279A

CN118236279A - Fusobacterium composition

Info

Publication number: CN118236279A
Application number: CN202311766674.8A
Authority: CN
Inventors: 犬伏顺也; 池乃上久美子; 阪本广志
Original assignee: Sunstar Inc
Current assignee: Sunstar Inc
Priority date: 2022-12-23
Filing date: 2023-12-21
Publication date: 2024-06-25
Also published as: JP2024091118A

Abstract

Fusobacterium composition. [ problem ] to provide a method capable of effectively sterilizing Fusobacterium. [ solution ] A composition for sterilizing Fusobacterium, comprising: (A) Lauryl sulfate, and (B) at least one selected from the group consisting of lauroyl glutamic acid and salts thereof.

Description

Fusobacterium composition

Technical Field

The present disclosure relates to a composition for sterilizing fusobacterium bacteria, and the like.

Background

Dental plaque (plaque) is a biofilm formed by the accumulation of microorganisms in the oral cavity, and is considered to be a cause of dental caries and periodontal disease. Thus, tartar control, and in particular inhibition of tartar formation, is important.

Generally, tartar is formed as follows. That is, a thin film of protein derived from saliva and physiological gingival crevicular fluid called "pellicle (Pellicle)" is first formed on the surface of the tooth, and facultative anaerobic bacteria (initial attachment bacteria) such as streptococcus are attached to the tooth surface through the pellicle. The initial attachment bacteria attach to mediator bacteria such as fusobacterium which are co-aggregated with various oral bacteria, and the later attachment bacteria such as Porphyromonas gingivalis (Porphyromonas gingivalis) and Treponema pallidum (Treponema denticola) which are anaerobic bacteria attach to/aggregate with the mediator bacteria, so that the tartar is mature. In particular, late-stage adhesion bacteria cause periodontal disease, and are known to be directly or indirectly involved in periodontal tissue destruction (for example, non-patent document 1).

Further, it has been reported that fusobacterium bacteria produce hydrogen sulfide, which is a main cause of bad breath (for example, non-patent document 2).

Prior art literature

Patent literature

Patent document 1: japanese patent laid-open No. 2022-097295

Non-patent literature

Non-patent document 1: j Dent Res 90 (11): 1271-1278,2011

Non-patent literature 2：mBio Volume 13,Issue 5(September/October 2022Volume 13Issue 5e01936-22)"Genetic Determinants of Hydrogen Sulfide Biosynthesis in Fusobacterium nucleatum Are Required for Bacterial Fitness,Antibiotic Sensitivity,and Virulence"

Disclosure of Invention

Problems to be solved by the invention

From the above, it can be said that effective sterilization of fusobacterium is important in preventing and/or improving periodontal disease and halitosis. Accordingly, the present inventors have studied a method capable of effectively sterilizing fusobacterium.

Solution for solving the problem

The present inventors have found that lauryl sulfate exerts an excellent bactericidal effect against fusobacterium bacteria, and have further studied for improving the bactericidal effect. As a result, it was found that the antibacterial effect of fusobacterium was further improved by combining lauroyl glutamic acid or a salt thereof with lauryl sulfate. Further studies have been conducted to find that the bactericidal effect of fusobacterium is further improved when isopropyl methylphenol and/or nicotinic acid or a salt thereof is further combined with lauryl sulfate and lauroyl glutamic acid or a salt thereof.

The present disclosure includes, for example, the subject matter described in the following items.

Item 1.

A composition for sterilizing fusobacterium bacteria, comprising:

(A) Lauryl sulfate

(B) At least one selected from the group consisting of lauroyl glutamic acid and salts thereof.

Item 2.

The composition of item 1, further comprising isopropyl methylphenol.

Item 3.

The composition of item 1 or 2, further comprising niacin or a salt thereof.

Item 4.

The composition according to item 3, which contains 10 parts by mass or less of nicotinic acid or a salt thereof per 1 part by mass of the component (B).

Item 5.

The composition according to any one of items 1 to 4, further comprising lauroyl sarcosinate and/or polyoxyethylated hydrogenated castor oil.

Item 6.

The composition according to any one of items 1 to 5, which is an oral composition.

Item 7.

The composition according to any one of claims 1 to 5, which is used for preventing or improving halitosis.

Item 8.

The composition of item 6 or 7 which is a mouthwash.

ADVANTAGEOUS EFFECTS OF INVENTION

Provided is a composition capable of effectively sterilizing Fusobacterium. The composition is effective for preventing and/or improving periodontal disease and halitosis, for example.

Drawings

FIG. 1 shows the viable count of Fusobacterium when aqueous solutions of sodium lauryl sulfate of various concentrations were used as bactericides.

FIG. 2 shows the viable count of Fusobacterium when various bactericides having different compositions (Table 1) were used.

FIG. 3A shows the viable count of Fusobacterium when isopropyl methylphenol solutions of various concentrations were used as bactericides.

FIG. 3B shows the viable count of Fusobacterium when various bactericides having different compositions (Table 3) were used.

FIG. 4 shows the viable count of Fusobacterium when various bactericides having different compositions (Table 4) were used.

Detailed Description

Each embodiment included in the present disclosure is described in more detail below. The present disclosure preferably includes a composition containing (a) lauryl sulfate and (B) at least one selected from the group consisting of lauroyl glutamic acid and salts thereof, uses thereof, and the like, but is not limited thereto, and the present disclosure includes all that is disclosed in the present specification, as will be understood by those skilled in the art. A composition containing (a) lauryl sulfate and (B) at least one selected from the group consisting of lauroyl glutamic acid and salts thereof is sometimes referred to as a composition of the present disclosure. The compositions of the present disclosure are particularly useful as fusobacterium bacteria killing agents. The lauryl sulfate may be referred to as component (a) and at least one selected from the group consisting of lauroyl glutamic acid and salts thereof may be referred to as component (B).

The bacterium of the genus Fusobacterium is not particularly limited as long as it is a mediator bacterium of the initial attachment bacterium and the later attachment bacterium in the formation of tartar, and Clostridium nucleatum (Fusobacterium nucleatum) is preferably exemplified.

The lauryl sulfate is preferably an alkali metal salt, an ammonium salt, or a triethanolamine salt of lauryl sulfate, more preferably sodium lauryl sulfate or potassium lauryl sulfate, and still more preferably sodium lauryl sulfate. The lauryl sulfate may be used alone or in combination of 2 or more.

The composition of the present disclosure preferably contains lauryl sulfate, for example, 0.01 to 0.5 mass%. The upper limit or the lower limit of the range may be, for example, 0.02, 0.05, 0.1, 0.2, 0.3, or 0.4 mass%. For example, the content may be 0.02 to 0.4 mass%.

The salt of lauroyl glutamic acid is preferably an alkali metal salt, an ammonium salt, or a triethanolamine salt, more preferably a sodium salt or a potassium salt, and further preferably a sodium salt. As lauroyl glutamic acid and salts thereof, 1 or 2 or more types may be used singly or in combination.

The composition of the present disclosure preferably contains the component (B) for example, 0.01 to 5 mass%. The upper or lower limit of the range may be, for example, 0.02, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 4.5 mass%. For example, the content may be 0.02 to 4% by mass.

The composition of the present disclosure preferably contains the component (B) and the component (A) in a mass ratio (B: A) of 1:0.1 to 5. The upper or lower limit of the range (0.1 to 5) may be, for example, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 4.5. The range may be, for example, 0.2 to 4 or 0.3 to 2.

The compositions of the present disclosure preferably also contain isopropyl methylphenol (IPMP). Isopropyl methylphenol is preferable because it can further improve the bactericidal effect of Fusobacterium obtained by combining the component (A) and the component (B).

When the composition of the present disclosure contains isopropyl methylphenol, it is preferable to contain 0.001 to 2 parts by mass per 1 part by mass of the component (B). The upper or lower limit of the range (0.001 to 2) may be 0.002、0.003、0.004、0.005、0.006、0.007、0.008、0.009、0.01、0.02、0.03、0.04、0.05、0.06、0.07、0.08、0.09、0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1、1.1、1.2、1.3、1.4、1.5、1.6、1.7、1.8 or 1.9, for example. For example, the range may be 0.002 to 1.5 or 0.005 to 1.

In the case where the composition of the present disclosure contains isopropyl methylphenol, it is preferable to contain 0.005 to 0.2% by mass. The upper or lower limit of the range may be 0.006、0.007、0.008、0.009、0.01、0.02、0.03、0.04、0.05、0.06、0.07、0.08、0.09、0.1、0.11、0.12、0.13、0.14、0.15、0.16、0.17、0.18、 or 0.19 mass%, for example. For example, the content may be 0.01 to 0.15 mass%.

The compositions of the present disclosure preferably further comprise niacin or a salt thereof. Nicotinic acid or a salt thereof is preferable because it can further improve the bactericidal effect of Fusobacterium obtained by combining the component (A) and the component (B).

The nicotinic acid salt is preferably an alkali metal salt, more preferably a sodium salt or a potassium salt, and further preferably a sodium salt. As the nicotinic acid or a salt thereof, 1 or 2 or more kinds may be used singly or in combination. Among them, niacin is preferred.

When the composition of the present disclosure contains nicotinic acid or a salt thereof, it is preferably contained in an amount of 10 parts by mass or less, more preferably 0.002 to 10 parts by mass, relative to 1 part by mass of the component (B). The upper limit or the lower limit of the range (0.002 to 10) may be 0.005、0.01、0.05、0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1、1.5、2、2.5、3、3.5、4、4.5、5、5.5、6、6.5、7、7.5、8、8.5、9、 or 9.5, for example. For example, the range may be 0.2 to 8 or 0.3 to 5.

In the case where the composition of the present disclosure contains nicotinic acid or a salt thereof, it preferably contains 0.01 to 2% by mass. The upper or lower limit of the range may be 0.02、0.03、0.04、0.05、0.06、0.07、0,08、0.09、0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1、1.1、1.2、1.3、1.4、1.5、1.6、1.7、1.8、 or 1.9 mass%, for example. For example, the content may be 0.1 to 1.5 mass%.

The composition of the present disclosure contains a component (a) useful for sterilizing fusobacterium and a component (B) capable of improving the bactericidal activity of fusobacterium lauryl sulfate, and thus can be preferably used for sterilizing fusobacterium. Furthermore, isopropyl methylphenol and/or nicotinic acid or a salt thereof can further enhance the fusobacterium sterilization by the combination of the component (a) and the component (B), and a composition further comprising these can be more preferably used as a fusobacterium sterilization composition.

In addition, as described above, it can be said that formation of tartar on the tooth surface can be suppressed by sterilizing fusobacterium bacteria, and therefore the composition of the present disclosure can be preferably used as a composition for inhibiting formation of tartar. Further, as described above, since it is reported that clostridium produces hydrogen sulfide, which is a main causative substance of halitosis, and1 species of clostridium is causative bacteria of halitosis, it can be said that halitosis can be prevented or ameliorated by sterilizing clostridium, and therefore the composition of the present disclosure can be preferably used as a composition for preventing and/or ameliorating halitosis. Thus, from this, it is clear that the composition of the present disclosure can be preferably used as an oral composition. The composition for oral cavity can be used preferably for inhibiting dental calculus formation, sterilizing Fusobacterium, and preventing and/or improving halitosis.

The compositions of the present disclosure can be solid compositions, liquid compositions. The composition can be used as a drug or quasi drug, for example. In addition, the form of the composition of the present disclosure is not particularly limited, and forms (dosage forms) such as ointments, pastes, dermatological pastes, gels, liquid preparations, sprays, mouthwash liquid preparations, liquid dentifrices, toothpastes, chewing gums, and the like may be formed according to conventional methods. Among them, mouthwash liquid preparations, liquid dentifrices, toothpastes, ointments, pastes, liquid preparations, gels are preferred.

The composition of the present disclosure may further contain, for example, any of the components alone or 2 or more components capable of being compounded into an oral composition, within a range that does not impair the effect.

For example, as the surfactant, a nonionic surfactant, an anionic surfactant, or an amphoteric surfactant may be compounded. Specifically, examples of the nonionic surfactant include sugar fatty acid esters such as sucrose fatty acid esters, maltose fatty acid esters, and lactose fatty acid esters; fatty acid alkanolamides; a glycerol fatty acid ester; sorbitan fatty acid esters; fatty acid monoglycerides; polyoxyethylene alkyl ether with polyoxyethylene addition coefficient of 8-10 and alkyl carbon number of 13-15; polyoxyethylene alkylphenyl ether having a polyoxyethylene addition coefficient of 10 to 18 and an alkyl group having 9 carbon atoms; diethyl sebacate; polyoxyethylene hydrogenated castor oil; fatty acid polyoxyethylene sorbitan, and the like. Examples of the anionic surfactant include sulfate salts such as sodium polyoxyethylene lauryl ether sulfate; sodium lauryl sulfosuccinate, sodium polyoxyethylene lauryl ether sulfosuccinate and other sulfosuccinates; acyl amino acid salts such as sodium cocoyl sarcosinate and sodium lauroyl methylalaninate; sodium cocoyl methyl taurate, and the like. Examples of the zwitterionic surfactant include acetic acid betaine type surfactants such as lauryl dimethyl amino acid betaine and coco fatty acid amidopropyl dimethyl amino acid betaine; imidazoline-type active agents such as N-cocoyl-N-carboxymethyl-N-hydroxyethyl ethylenediamine sodium; amino acid type active agents such as N-lauryldiaminoethylglycine, etc. These surfactants may be compounded alone or in combination of 2 or more. The amount to be compounded is usually 0.1 to 5% by mass based on the total amount of the composition. Although not particularly limited, the composition of the present disclosure preferably contains polyoxyethylene hydrogenated castor oil. The polyoxyethylene addition coefficient is preferably about 20 to 80, more preferably about 30 to 60. The polyoxyethylene hydrogenated castor oil preferably contains, for example, 0.05 to 2% by mass.

Examples of the flavoring agents include menthol, carboxylic acid, anethole, eugenol, methyl salicylate, limonene, ocimene, n-decanol, citronellal, α -terpineol, methyl acetate, citronellyl acetate, methyl eugenol, eucalyptol, linalool, ethyl linalool, thymol, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, cassia oil, perilla oil, wintergreen oil, clove oil, eucalyptus oil, multi-bergamot oil, d-camphor, fennel oil, cinnamon oil, cinnamaldehyde, peppermint oil, and vanillin. These may be compounded singly or in combination of 2 or more kinds, for example, in an amount of 0.001 to 1.5% by mass relative to the total amount of the composition.

As the sweetener, sodium saccharin, potassium acesulfame, stevioside, neohesperidin dihydrochalcone, perillyl, thaumatin, aspartyl phenylalanine methyl ester, p-methoxycinnamaldehyde, and the like can be used, for example. They may be compounded, for example, in an amount of 0.01 to 1% by mass relative to the total amount of the composition.

Further, as the wetting agent, 2 or more kinds of sorbitol, ethylene glycol, propylene glycol, glycerin, 1, 3-butanediol, polypropylene glycol, xylitol, maltitol, lactitol, polyoxyethylene glycol, and the like may be blended singly or in combination.

As the preservative, there may be blended methyl benzoate, ethyl benzoate, propyl benzoate, butyl benzoate and other parabens, sodium benzoate, phenoxyethanol, alkyldiaminoethyl glycine hydrochloride and the like.

The colorant may be mixed with a legal pigment such as blue No. 1, yellow No. 4, red No. 202, green No. 3, a mineral pigment such as ultramarine, enhanced ultramarine, prussian blue, or the like, titanium oxide, or the like.

As the pH adjuster, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid, or chemically acceptable salts thereof, sodium hydroxide, or the like may be blended. They may be compounded alone or in combination of 2 or more in such a manner that the pH of the composition is in the range of 4 to 8, preferably 5 to 7. The blending amount of the pH adjustor may be, for example, 0.01 to 2 wt%.

In the composition of the present disclosure, not only dodecylpyridinium chloride but also 2 or more enzymes such as dl- α -tocopherol acetate, tocopherol succinate, tocopherol nicotinate and the like, an amphoteric bactericide such as dodecyldiaminoethyl glycine and the like, a nonionic bactericide such as triclosan and hinokitiol, an anionic bactericide such as lauroyl sarcosinate, a cationic bactericide such as cetylpyridinium chloride, chlorhexidine hydrochloride, benzalkonium chloride, benzethonium chloride, glucanase, amylase, protease, non-water-soluble glucanase, lysozyme (lysozyme), enzymes such as lysozyme (lytic enzyme), alkali metal monofluorophosphate such as sodium monofluorophosphate, sodium fluoride, fluoride such as stannous fluoride, fluorochromic acid, epsilon-aminocaproic acid, chlorohydroxy allantoin aluminum, dihydrocholesterol, glycyrrhetinic acid, glycyrrhizic acid, copper chlorophyllin sodium, glycerophosphate, chlorophyll, sodium chloride, carropeptide, sodium nitrate, sodium sulfonate, sodium sulfanilate, cyproconazole, and the like may be blended as the active ingredient.

Although not particularly limited, lauroyl sarcosinate (preferably sodium or potassium salt, more preferably sodium salt) is preferably contained in the composition of the present disclosure. The lauroyl sarcosinate is preferably contained in an amount of 0.01 to 2% by mass, for example.

Further, alcohols, silicon, apatite, white vaseline, paraffin, liquid paraffin, microcrystalline wax, squalane, liquid paraffin, and a polyethylene compound ointment base (plasitibase) may be added as the base.

In addition, the compositions of the present disclosure may be prepared using known methods or methods readily contemplated by known methods. For example, it can be prepared by appropriately mixing dodecylpyridinium chloride with glycyrrhizic acid or a salt thereof, and other components as required.

The object to which the composition of the present disclosure is applied is not particularly limited, and human and non-human mammals are preferably exemplified. The non-human mammal is preferably livestock, pet, or the like, and more specifically, dogs, cats, mice, rats, horses, cows, sheep, monkeys, or the like, for example, may be mentioned. In addition, the composition of the present disclosure is not particularly limited, and as described above, since the dodecylpyridinium chloride can effectively sterilize fusobacterium which is a mediator bacterium, it can be said that the composition is particularly suitable for application to an oral cavity of a subject in which tartar is not formed or in the middle of formation (in which post-attachment bacteria are not attached).

The composition of the present disclosure can be applied directly to, for example, a composition for inhibiting tartar formation which is not used as an oral composition, or a composition containing the fusobacterium bactericide (for example, when the composition is used for cleaning a denture).

The term "comprising" in this specification also includes "consisting essentially of … …" and "consisting of … …" (The term "comprised" included "consisting essentially of" and "consisting of."). In addition, the present disclosure includes any combination of the constituent conditions described in the present specification.

In addition, when the subject matter contained in the present disclosure is specified with respect to various characteristics (properties, structures, functions, and the like) described in the above embodiments of the present disclosure, any combination may be adopted. That is, the present disclosure includes all subjects including any combination of the characteristics that can be combined as described in the present specification.

Examples (example)

The following examples are shown to more specifically describe embodiments of the present disclosure, but embodiments of the present disclosure are not limited by the following examples. In the following diagrams, sodium lauryl sulfate may be referred to as SLS, sodium lauroyl sarcosinate as LS, sodium lauroyl glutamate as LG, and nicotinic acid as NA. The values of the components in the table represent mass% unless otherwise specified.

An aqueous solution of 0.05 mass%, 0.1 mass%, 0.5 mass%, or 1.0 mass% of sodium lauryl sulfate was produced to form a bactericide liquid.

The bactericide liquids of the comparative examples and examples were produced according to the compositions shown in table 1. In the compositions of each of examples and comparative examples shown in table 1, sodium saccharin, polyethylene glycol (PEG), and polyoxyethylene alkyl (12 to 14) sodium sulfosuccinate 2 were added in appropriate amounts in addition to the components shown in table 1, and water was added thereto to form 100 mass% of the total. These components were added in equal amounts to each other in any case.

TABLE 1

In addition, 2 subspecies of the following Fusobacterium were used as test bacteria.

Bacteria 1: fusobacterium nucleatum subspecies (Fusobacterium nucleatum subsp. Nucleatum) ATCC23726

Bacteria 2: fusobacterium nucleatum subspecies (Fusobacterium nucleatum subsp. Nucleatum) ATCC25586

Study 1

The test bacteria were inoculated into 10ml of GAM broth (Nikkin pharmaceutical Co., ltd.) and cultured anaerobically at 37℃for 2 days. The culture solution was used as a test bacterial solution.

200. Mu.l of a test bacterial solution was mixed with 200. Mu.l of aqueous sodium lauryl sulfate solutions (disinfectant solutions) having different concentrations. After 30 seconds from the mixing, 100. Mu.l of the mixture was collected, 900. Mu.l of PBS for inactivation of the drug was added (10-fold dilution of the mixture), and the bactericidal effect of the bactericide was inactivated. The drug-inactivated PBS was prepared by adding soybean lecithin and Tween 80 to phosphate-buffered saline (PBS) so that the final concentrations thereof were 0.07% and 0.5%. The mixture was diluted in stages with the agent-inactivated PBS, and the mixture was diluted 10 ¹～10⁷ times (stage mixture dilution).

The produced dilutions of the step mixture were spread on sheep blood agar medium (Becton, dickinson and Company, japan) for CDC anaerobe, and anaerobically cultured at 37℃for 3 days, and the number of viable bacteria was counted. From the obtained results, log (viable count) CFU/ml was calculated. Note that Log is a common logarithm.

The results are shown in FIG. 1. The results when water was used instead of the aqueous sodium lauryl sulfate solution are also shown. It is known that lauryl sulfate exerts the bactericidal effect of fusobacterium.

Study 2

For the test bacteria, each of Fusobacterium (bacteria 1 or 2) was inoculated into 10ml of GAM broth (Nikki pharmaceutical Co., ltd.) and cultured anaerobically at 37℃for 2 days. After cultivation, a bacterial density of about 10 ⁸～10⁹ CFU/ml was obtained. The culture broth was centrifuged (3000 rpm,10 min, 4 ℃) and the supernatant was discarded and the cells (about 10 ⁹～10¹⁰ CFU) recovered.

10Ml of resting saliva was collected from 1 healthy adult, and the cell was mixed with the saliva (about 10 ⁹～10¹⁰ CFU). After mixing, the mixture was uniformly dispersed to produce Fn with high saliva content (about 10 ⁸～10⁹ CFU/saliva 1 ml). Fn represents "Fusobacterium".

The respective bactericide liquids (bactericides of respective examples shown in table 1) having different concentrations were mixed with Fn to contain saliva. The mixing ratio was set to be Fn high with saliva=1:1 (200. Mu.L: 200. Mu.L) or 1:9 (100. Mu.L: 900. Mu.L) as the bactericide liquid. After 30 seconds from the mixing, 100. Mu.l of the mixture was collected, 900. Mu.l of PBS for inactivation of the drug was added (10-fold dilution of the mixture), and the bactericidal effect of the bactericide was inactivated. The drug-inactivated PBS was prepared by adding soybean lecithin and Tween 80 to phosphate-buffered saline (PBS) so that the final concentrations thereof were 0.07% and 0.5%.

Each 100. Mu.l of the prepared mixture was smeared on sheep blood agar medium (Becton, dickinson and Company, japan) for CDC anaerobic bacteria, and anaerobic culture was performed at 37℃for 3 days, and the number of viable bacteria was counted. From the obtained results, log (viable count) CFU/ml was calculated. Note that Log is a common logarithm.

The results are shown in Table 2 and FIG. 2. The results were obtained by conducting a study using a mixture ratio of bacteria 2, a bactericide liquid and Fn, which is high in saliva, of 1:9. The results of using a 0.2 mass% aqueous solution of sodium lauryl sulfate as the bactericide liquid and using water instead of the bactericide liquid are also shown.

TABLE 2

	Log (viable count) CFU/ml
		0.2% SLS aqueous solution	6.35
Comparative example 1a	6.37
		Comparative example 2a	6.31
Comparative example 3a	6.47
		Comparative example 4a	6.28
Comparative example 5a	6.50
		Comparative example 6a	7.60
Example 1a	4.32
		Example 2a	4.44
Comparative example 7a	6.50
		Comparative example 8a	6.60
Water and its preparation method	7.02

Since only the bactericidal activity of the fusobacterium of examples 1a and 2a was improved, it was found that the bactericidal effect of the fusobacterium by lauryl sulfate was enhanced by the combined use of lauroyl glutamic acid or a salt thereof.

In addition, 0.025 mass% or 0.05 mass% solution of isopropyl methylphenol (IPMP) was produced, and the bactericidal activity against fusobacterium was studied using the method of study 1 described above, using this as a bactericidal agent. The isopropyl methylphenol solution was an aqueous ethanol solution having a final concentration of 10 mass%.

Further, the bactericidal liquid of each comparative example and example was produced according to the composition shown in table 3, and the bactericidal activity against fusobacterium was studied using Fn high-content saliva as described above. In the compositions of examples and comparative examples shown in table 3, sodium saccharin, polyethylene glycol (PEG), and polyoxyethylene alkyl (12 to 14) sodium sulfosuccinate 2 were added in appropriate amounts in addition to the components shown in table 3, and water was added thereto to form 100 mass% of the total. These components were added in equal amounts to each other in any case.

TABLE 3

The results when using an isopropyl methylphenol solution as a bactericide are shown in fig. 3A. The results were obtained by conducting a study using a mixing ratio of 1:1 of the bacteria 1, the bactericide liquid and the test bacteria liquid. In addition, the results obtained when a 10 mass% aqueous ethanol solution was used in place of the isopropyl methylphenol solution are also shown.

The results of using the bactericides of each example described in table 3 are shown in fig. 3B. The results were obtained by conducting a study using a mixture ratio of bacteria 1, a bactericide liquid and Fn, which is high in saliva, of 1:9. The results when water was used instead of the bactericide liquid are also shown.

From these results, it is understood that isopropyl methylphenol does not exert the bactericidal effect of fusobacterium, but the bactericidal effect of fusobacterium is further enhanced by further combining isopropyl methylphenol with lauryl sulfate and lauroyl glutamic acid or a salt thereof.

Further, the bactericidal liquid of each comparative example and example was produced according to the composition shown in table 4, and the bactericidal activity against fusobacterium was studied using Fn high-content saliva as described above. In the compositions of examples and comparative examples shown in table 4, sodium saccharin, polyethylene glycol (PEG), and polyoxyethylene alkyl (12 to 14) sodium sulfosuccinate 2 were added in appropriate amounts in addition to the components shown in table 4, and water was added thereto to form 100 mass% of the total. These components were added in equal amounts to each other in any case.

TABLE 4

The results are shown in FIG. 4. The results were obtained by conducting a study using a mixture ratio of bacteria 1, a bactericide liquid and Fn, which is high in saliva, of 1:9. The results when water was used instead of the bactericide liquid are also shown.

From the results, it is understood that the bactericidal effect of fusobacterium can be further enhanced by further combining niacin with lauryl sulfate and lauroyl glutamic acid or a salt thereof. It is also unexpectedly found that the effect of enhancing the bactericidal effect is highly likely to be low in the amount of nicotinic acid.

Claims

1. (A) Lauryl sulfate

(B) At least one selected from the group consisting of lauroyl glutamic acid and salts thereof

The application in the manufacture of the composition for sterilizing Fusobacterium.

2. (A) Lauryl sulfate,

(B) At least one selected from the group consisting of lauroyl glutamic acid and salts thereof, and

Isopropyl methylphenol and/or nicotinic acid or salts thereof

3. (A) Lauryl sulfate,

Isopropyl methylphenol and niacin or salts thereof

4. The use according to claim 2 or 3, wherein 10 parts by mass or less of nicotinic acid or a salt thereof is used with respect to 1 part by mass of the component (B).

5. Use according to claim 1,2 or 3, wherein the fusobacterium bactericidal composition further comprises lauroyl sarcosinate and/or polyoxyethylated hydrogenated castor oil.

6. The use according to claim 1, 2 or 3, wherein the fusobacterium bactericidal composition is an oral composition.

7. The use according to claim 1, 2 or 3, wherein the fusobacterium bactericidal composition is for halitosis prevention or improvement.

8. The use according to claim 1, 2 or 3, wherein the fusobacterium bactericidal composition is a mouthwash.